The Sodium Channel Protein Type 10 Subunit Alpha pipeline drugs market research report outlays comprehensive information on the Sodium Channel Protein Type 10 Subunit Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sodium Channel Protein Type 10 Subunit Alpha pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Toxicology, Genetic Disorders, and Gastrointestinal which include the indications Post-Operative Pain, Pain, Chemotherapy Induced Peripheral Neuropathy, Genetic Disorders, Erythromelalgia, and Oral Mucositis. It also reviews key players involved in Sodium Channel Protein Type 10 Subunit Alpha targeted therapeutics development with respective active and dormant or discontinued products.
The Sodium Channel Protein Type 10 Subunit Alpha pipeline targets constitutes close to 42 molecules. Out of which, approximately 41 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 9, 8, 1, 12, and 5 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Sodium Channel Protein Type 10 Subunit Alpha overview
Sodium channel proteintType 10 subunit alpha (SCN10A) is a protein that in humans is encoded by the SCN10A gene. SCN10A encodes a voltage-gated sodium channel alpha subunit, which is a protein that forms the pore of a sodium channel. Sodium channels are found in the membranes of excitable cells, such as nerve cells and muscle cells. They allow sodium ions to flow into the cell when the membrane potential is depolarized. This influx of sodium ions triggers the action potential, which is the electrical signal that allows these cells to communicate with each other.
For a complete picture of Sodium Channel Protein Type 10 Subunit Alpha’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
